Acetylcysteine - Reduction of sputum viscosity
You are here : Home > Formulary Search > Acetylcysteine - Reduction of sputum viscosity
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green (see narrative)
Formulations :
- Effervescent tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Prescribe generically as 600mg effervescent tablets sugar free.
Do not use in patients with bronchospasm or history of asthma.
Do not use in fluid or sodium restricted patients.
Documents :
Guidelines (Local)
Status 2
Non Formulary
Formulations :
- Capsules
- Granules
- Oral solution
- Powder
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
These are either unlicensed or are not considered cost-effective treatment options - see guidelines for recommended products.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Acetylcysteine
Indication :
Reduction of sputum viscosity
Group Name :
Keywords :
excessive mucous production, mucolytics, COPD, Bronchiectasis
Brand Names Include :
NACSYS, A-CYS, AceCil, Acepiro
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2
Other Indications
Below are listed other indications that Acetylcysteine is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Reduction of sputum viscosity.
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee approved the Primary Care guidance for prescribing oral mucolytics.
Acetylcysteine should be prescribed generically.
Refer to the guidance for full details.